Try our mobile app

Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study

Published: 2021-09-30 08:30:00 ET
<<<  go to LLY company page

Participants taking highest dose of tirzepatide experienced 91.2% time in range (71-180 mg/dL) and 72.6% time in tight target range (71-140 mg/dL)

CGM sub-study achieved its primary and secondary endpoints

INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a continuous glucose monitoring (CGM) sub-study1 of Eli Lilly and Company's (NYSE: LLY) phase 3 SURPASS-3 clinical trial. The CGM sub-study was presented today at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting in an EASD-sponsored symposium.

The international consensus for time in range recommends a target of >70% time in range (70-180 mg/dL) for most people with diabetes as well as a target of